Abstract
Inhibitor development is a serious complication of hemophilia A treatment. Although studies of inhibitor prevalence had been published earlier,1–3 the possibility that there is increased risk of inhibitor formation with different Factor VIII (F.VIII)-containing products was first raised when heat-treated concentrates were introduced. However, this concern was quickly dropped when it was apparent that heat treatment was necessary to inactivate HIV. As a result, no systematic study during the 1980s directly compared heat treated and non-heat treated F.VIII concentrates.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
C.K. Kasper. Incidence and course of inhibitors among patients with classic hemophilia, Thromb.etDiath.Haem.30:263 (1973).
H.S. Strauss. Acquired circulating anticoagulants in hemophilia A, N. Engl J. Med.281:866 (1969).
C.W. McMillan, S.S. Shapiro, D. Whitehurst, et al. The natural history of factor VIII:C inhibitors in patients with hemophilia A:A national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors, Blood71:344 (1988).
B.A. Bell, E.M. Kurczynski and G. Bergman. Inhibitors to monoclonal antibody purified factor VIII, Lancet336:638 (1990).
CM. Kessler and K. Sachse. Factor VIILC inhibitor associated with monoclonal- 44 antibody purified FVIII concentrate, Lancet335:1403 (1990).
J.E. Addiego, Jr., E.D. Gomperts, S.-L. Liu, et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography, Thromb.Haem.67:19 (1992).
J.M. Lusher, P.M. Salzman and Monoclate Study Group. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to Factor VIIIC concentrates, SeminHematol 27:1 (1990).
K. Peerlinck, J. Arnout, J.G. Gilles, J.M. Saint-Remy and J. Vermylen. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate, ThrombHaem. 69:115 (1993).
F.R. Rosendaal, H.K. Nieuwenhuis, H.M. van den Berg, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands, Blood8:2180 (1993).
R.S. Schwartz, CF. Abildgaard, L.M. Aledort, et al. Human recombinant DNA-derived antihemophilic factor (Factor VIII) in the treatment of hemophilia A, N. Engl J.Med.323:1800 (1990).
G.C. White, C.W McMillan, H.S. Kingdon and C.B. Shoemaker. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia, N. Engl J. Med.320:166 (1989).
G.L. Bray. Current status of clinical studies of recombinant factor VIII (Recombinate®) in patients with hemophilia A, Trans.Med.Rev.VI:252 (1992).
E.G.D. Tuddenham, D.N. Cooper, J. Gitschier, et al. Haemophilia A:database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, Nucl. Acids Res.19:4821 (1991).
R. Pozzatti, J. Vogel and G. Jay. The human lymphotropic T virus type I taxgene can cooperate with the RAS oncogene to induce neoplastic transformation of cells, Mol. Cell. Biol.10:413 (1990).
L.E. Lippert, L.M. Fisher and L.B. Schook. Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A, Thromb.Haem. 64:564 (1990).
A.M. Aly, L.M. Aledort, T.D. Lee and L.W. Hoyer. Histocompatibility antigen patterns in hemophilic patients with factor VIII antibodies, BrJ.Haematol76:238 (1990).
D. Frommel, J.P. Allain, E. Saint-Paul, et al. HLA antigens and factor VIII antibody in classic hemophilia. European study group of factor VIII antibody, Thromb.Haem.46:687 (1981).
European Study Group of Factor VIII Antibody. Development of factor VIII antibody in haemophilic monozygotic twins, ScandJ. Haemat.23:64 (1979).
K. Peerlinck, F.R. Rosendaal and J. Vermylen. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood81:3332 (1993).
R. Schwaab, M. Ludwig, J. Oldenburg, et al. Identical point mutations in the factor VIII gene that have different clinical manifestations of hemophilia A, Am.J.Hum.Genet.47:743 (1990).
E.L. Kaplan and P. Meier. Nonparametric estimation from incomplete observations, J.Am.Statist.Assn.53:457 (1958).
M.L. Lee, S. Liu-Maruya, S. Courter and E. Gomperts. Determining inhibitor-development risk in previously untreated hemophilia A patients treated (PUPs) with recombinant factor VIII (recombinate™), Blood80:49la (1992).
J. Addiego, C. Kasper, C. Abildgaard, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII, Lancet342:462 (1993).
S. Ehrenforth, W. Kreuz, I. Scharrer, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs, Lancet339:594 (1992).
V. Rasi and E. Ikkala. Haemophiliacs with factor VIII inhibitors in Finland prevalence, incidence and outcome, BrJ.Haematol.76:369 (1990).
R. De Biasi, A. Rocino, M.L. Papa and E. Salerno. Incidence of inhibitor development in hemophilia A patients, Thromb.Haem.69:1103 (1993).
G.L. Bray, E.D. Gomperts, S. Courter, et al. A multi-center study of recombinant factor VIII (Recombinate):Safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A, Blood(1993).
J.M. Lusher, S. Arkin, C.F. Abildgaard, R.S. Schwartz and Kogenate. Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A, N.EnglJ.Meda.328:453 (1993).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Plenum Press, New York
About this chapter
Cite this chapter
Hoyer, L.W. (1995). The incidence of factor VIII inhibitors in patients with severe hemophilia A. In: Aledort, L.M., Hoyer, L.W., Lusher, J.M., Reisner, H.M., White, G.C. (eds) Inhibitors to Coagulation Factors. Advances in Experimental Medicine and Biology, vol 386. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0331-2_3
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0331-2_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8001-6
Online ISBN: 978-1-4613-0331-2
eBook Packages: Springer Book Archive